Magnitude and time course of platelet inhibition with Aggrenox® and Aspirin in patients after ischemic stroke: The AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial

European Journal of Pharmacology

Volumn 499, Issue 3, 2004, Pages 315-324

  Serebruany, Victor L ^a   Malinin, Alex I ^a   Sane, David C ^b   Jilma, Bernd ^c   Takserman, Aviv ^d   Atar, Dan ^d   Hennekens, Charles H ^e  

^a HeartDrug Research Laboratories   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e Miami Heart Inst   (United States)

Author keywords

Aggrenox ; Aspirin; Platelet; Randomized trial; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CD31 ANTIGEN; CD63 ANTIGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IIB; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN RECEPTOR;

ADULT; AGED; ARTICLE; AUTOANALYZER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SAMPLE SIZE; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

EID: 4544387953     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.07.114     Document Type: Article

References (45)

1. O.O. Akinboboye, O. Idris, R.L. Chou, R.R. Sciacca, P.J. Cannon, and S.R. Bergmann Absolute quantitation of coronary steal induced by intravenous dipyridamole J. Am. Coll. Cardiol. 37 2001 109 116
2. Antithrombotic Trialists Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
3. K.A. Ault Flow cytometric measurement of platelet function and reticulated platelets Ann. N.Y. Acad. Sci. 677 1993 293 308
4. L.F. Brass, S. Pizarro, M. Ahuja, E. Belmonte, N. Blanchard, J.M. Stadel, and J.A. Hoxie Changes in the structure and function of the human thrombin receptor during receptor activation, internalization, and recycling J. Biol. Chem. 269 1994 2934 2952
5. H. Bult, H.R.L. Fret, F.H. Jordaens, and A.G. Herman Dipyridamole potentiates the anti-aggregating and vasodilator activity of nitric oxide Eur. J. Pharmacol. 199 1991 1 8
6. S. Ciferri, C. Emiliani, G. Guglielmini, A. Orlacchio, G.G. Nenci, and P. Gresele Platelets release their lysosomal content in vivo in humans upon activation Thromb. Haemost. 83 2000 157 164
7. V. Costantini, A. Talpacci, M.L. Bastiano, E. Boschetti, S. Cipolloni, R. Bisacci, and G.G. Nenci Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study Biomed. Biochim. Acta 49 1990 263 271
8. L.D. Cupit, V.A. Schmidt, and W.F. Bahou Proteolitically activated receptor: 3. A member of an emerging gene family of protease receptors expressed on vascular endothelial cells and platelets Trends Cardiovasc. Med. 9 1999 42 48
9. J. De La Cruz, B. Encarnacion, and F. Sanchez de la Cuesta Effect of dipyridamole and aspirin on the plateletâ€"neutrophil interaction via the nitric oxide pathway Eur. J. Pharmacol. 397 2000 35 41
10. H.C. Diener, L. Cunha, C. Forbes, J. Sivenius, P. Smets, and A. Lowenthal European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke J. Neurol. Sci. 143 1996 1 13
11. V.M. Dixit, D.M. Haverstick, K.M. O'Rourke, S.W. Hennessy, G.A. Grant, S.A. Santoro, and W.A. Frazier A monoclonal antibody against human thrombospondin inhibits platelet aggregation Proc. Natl. Acad. Sci. U. S. A. 82 1985 3472 3476
12. A. Eldor, I. Vlodavsky, Z. Fuks, T.H. Muller, and W.G. Eisert Different effects of aspirin, dipyridamole and UD-CG 115 on platelet activation in a model of vascular injury: studies with extracellular matrix covered with endothelial cells Thromb. Haemost. 56 1986 333 339
13. W.G. Eisert Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells Neurology 57 2001 S20 S23
14. G.A. Fitzgerald Drug therapy: dipyridamole N. Engl. J. Med. 316 1987 1247 1257
15. M. Febbraio, and R.L. Silverstein Identification and characterization of LAMP-1 as an activation-dependent platelet surface glycoprotein J. Biol. Chem. 265 1990 18531 18537
16. C.R. Gibbs, and G.Y. Lip Do we still need dipyridamole? Br. J. Clin. Pharmacol. 45 1998 323 328
17. C.H. Hennekens Update on aspirin in treatment and prevention of cardiovascular disease Am. J. Manag. Care 8 2002 S692 S700
18. J. Himmelfarb, and L. Couper Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation Kidney Int. 52 1997 1671 1677
19. T. Ichii, H. Koyama, S. Tanaka, A. Shioi, Y. Okuno, S. Otani, and Y. Nishizawa Thrombospondin-1 mediates smooth muscle cell proliferation induced by interaction with human platelets Arterioscler. Thromb. Vasc. Biol. 22 2002 1286 1292
20. L. Iuliano, J.Z. Pedersen, G. Rotilio, D. Ferro, and F. Violi A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole Free Radic. Biol. Med. 18 1995 239 247
21. M.L. Kahn, M. Nakanishi-Matsui, and M.J. Shapiro Protease activated receptors 1 and 4 mediate activation of human platelets by thrombin Clin. Invest. 103 1999 879 887
22. S. Laferte, and J.W. Dennis Purification of two glycoproteins expressing beta 1â€"6 branched Asn-linked oligosaccharides from metastatic tumour cells Biochem. J. 259 1989 569 576
23. J. Lawler The functions of thrombospondin-1 and -2 Curr. Opin. Cell Biol. 12 2000 634 640
24. R.A. Majack, J. Mildbrandt, and V.M. Dixit Induction of thrombospondin messenger RNA levels occurs as an immediate primary response to platelet-derived growth factor J. Biol. Chem. 262 1987 8821 8825
25. E.F. Mammen, P.C. Comp, R. Gosselin, C. Greenberg, W.K. Hoots, C.M. Kessler, E.C. Larkin, D. Liles, and D.J. Nugent PFA-100 system: a new method for assessment of platelet dysfunction Semin. Thromb. Hemost. 24 1998 195 202
26. M.E. McKenzie, A.I. Malinin, C.R. Bell, A. Dzhanashvili, E.D. Horowitz, B.R. Oshrine, D. Atar, and V.L. Serebruany Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets Blood Coagul. Fibrinolysis 14 2003 249 253
27. T.H. Muller, C.A. Su, H. Weisenberger, R. Brickl, G. Nehmiz, and W.G. Eisert Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo Br. J. Clin. Pharmacol. 30 1990 179 186
28. T.H. Muller Inhibition of thrombus formation by low-dose acethylsalycilic acid, dipyridamole, and their combination in a model of platelet†"vessel wall interaction Neurology 57 2001 S8 S11
29. G.G. Neri Serneri, G. Masotti, L. Poggesi, G. Galanti, and A. Morettini Enhanced prostacyclin production by dipyridamole in man Eur. J. Clin. Pharmacol. 21 1981 9 15
30. R.I. Parker, and H.R. Gralnick Effect of aspirin on platelet-von Willebrand factor surface expression on thrombin and ADP-stimulated platelets Blood 74 1989 2016 2021
31. Z.M. Ruggeri New insights into the mechanisms of platelet adhesion and aggregation Semin. Hematol. 31 1994 229 239
32. A.J. Schade, M. Arya, S. Gao, R. Diz-Kucukkaya, B. Anvari, L.V. McIntire, J.A. Lopez, and J.F. Dong Cytoplasmic truncation of glycoprotein Ib alpha weakens its interaction with von Willebrand factor and impairs cell adhesion Biochemistry 42 2003 2245 2251
33. K.A. Schwartz, D.E. Schwartz, R.A. Pittsley, S.L. Mantz, G. Ens, A. Sami, and J.M. Davis A new method for measuring inhibition of platelet function by nonsteroidal antiinflammatory drugs J. Lab. Clin. Med. 139 2002 227 233
34. M.L. Selly, A.L. Czeti, J.A. McGuiness, and N.G. Ardlie Dipyridamole inhibits the oxidative modification of low density lipoprotein Atherosclerosis 111 1994 91 97
35. V.L. Serebruany, and P.A. Gurbel The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin? Thromb. Haemost. 81 1999 314 316
36. V.L. Serebruany, M.E. McKenzie, D.J. Levine, and P.A. Gurbel Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something? Thromb. Haemost. 83 2000 356 357
37. V.L. Serebruany, A.I. Malinin, and D.C. Sane Rapid platelet inhibition after a single pill Aggrenox®: challenging a conventional full-dose aspirin antiplatelet advantage? Am. J. Hematol. 72 2003 280 281
38. V.L. Serebruany, A.I. Malinin, B.R. Oshrine, D.C. Sane, A. Takserman, D. Atar, and C.H. Hennekens Lack of uniformed platelet activation in patients after ischemic stroke and choice of antiplatelet therapy Thromb. Res. 113 2004 197 204
39. J.P. Singh, K.J. Rothfuss, T.R. Wiernicki, W.B. Lacefield, W.L. Kurtz, R.F. Brown, K.A. Brune, D. Bailey, and G.P. Dube Dipyridamole directly inhibits vascular smooth muscle cell proliferation in vitro and in vivo: implications in the treatment of restenosis after angioplasty J. Am. Coll. Cardiol. 23 1994 665 671
40. J.W. Smith, S.R. Steinhubl, A.M. Lincoff, J.C. Coleman, T.T. Lee, R.S. Hillman, and B.S. Coller Rapid platelet-function assay: an automated and quantitative cartridge-based method Circulation 99 1999 620 625
41. G.P. Tuszynski, V.L. Rothman, A. Murphy, K. Siegler, and K.A. Knudsen Thrombospondin promotes platelet aggregation Blood 72 1988 109 115
42. G.H. van Zanten, S. de Graaf, P.J. Slootweg, H.F. Heijnen, T.M. Connolly, P.G. de Groot, and J.J. Sixma Increased platelet deposition on atherosclerotic coronary arteries J. Clin. Invest. 93 1994 615 632
43. G.H. van Zanten, H.F. Heijnen, Y. Wu, K.M. Schut-Hese, P.J. Slootweg, P.G. de Groot, J.J. Sixma, and R. Nieuwland A fifty percent reduction of platelet surface glycoprotein Ib does not affect platelet adhesion under flow conditions Blood 9 1998 2353 2359
44. T.-K.H. Vu, D.T. Hung, and V.I. Wheaton Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation Cell 64 1991 1057 1068
45. Z. Xiao, P. Theroux, and M.M. Frojmovic Modulation of plateletâ€"neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor Thromb. Haemost. 81 1991 281 285